Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.

Herrera AF, Molina A.

Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):452-468.e4. doi: 10.1016/j.clml.2018.05.006. Epub 2018 May 10. Review.

2.

Emerging antibody-drug conjugates for treating lymphoid malignancies.

Wolska-Washer A, Robak P, Smolewski P, Robak T.

Expert Opin Emerg Drugs. 2017 Sep;22(3):259-273. doi: 10.1080/14728214.2017.1366447. Epub 2017 Aug 28. Review.

PMID:
28792782
3.

Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens.

Lu D, Gillespie WR, Girish S, Agarwal P, Li C, Hirata J, Chu YW, Kagedal M, Leon L, Maiya V, Jin JY.

CPT Pharmacometrics Syst Pharmacol. 2017 Jun;6(6):401-408. doi: 10.1002/psp4.12192. Epub 2017 May 23.

4.

New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.

Merli M, Ferrario A, Maffioli M, Olivares C, Stasia A, Arcaini L, Passamonti F.

Expert Rev Hematol. 2016 Aug;9(8):767-80. doi: 10.1080/17474086.2016.1205949. Epub 2016 Jul 14. Review.

PMID:
27416486
5.

Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.

Mehta A, Forero-Torres A.

Curr Oncol Rep. 2015 Sep;17(9):41. doi: 10.1007/s11912-015-0466-9. Review.

PMID:
26194424
6.

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F.

Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27.

PMID:
25925619
7.

Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.

Merli M, Ferrario A, Maffioli M, Arcaini L, Passamonti F.

Expert Opin Investig Drugs. 2015;24(7):897-912. doi: 10.1517/13543784.2015.1038342. Epub 2015 Apr 21. Review.

PMID:
25900401
8.

A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.

Yu SF, Zheng B, Go M, Lau J, Spencer S, Raab H, Soriano R, Jhunjhunwala S, Cohen R, Caruso M, Polakis P, Flygare J, Polson AG.

Clin Cancer Res. 2015 Jul 15;21(14):3298-306. doi: 10.1158/1078-0432.CCR-14-2035. Epub 2015 Apr 3.

10.

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dörken B, Chu YW, Chen AI, Lebovic D, Salles GA, Czuczman MS, Palanca-Wessels MC, Press OW, Advani R, Morschhauser F, Cheson BD, Lenz P, Ott G, Polson AG, Mundt KE, Lenz G.

Leukemia. 2015 Jul;29(7):1578-86. doi: 10.1038/leu.2015.48. Epub 2015 Feb 24.

PMID:
25708834

Supplemental Content

Loading ...
Support Center